Nektar Therapeutics
NKTR
查看详细走势图
43.940USD
-0.520-1.17%
收盘 12/24, 13:00（美东）报价延迟15分钟
863.53M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.17%
5天
-3.28%
1月
-25.07%
6月
+360.59%
今年开始到现在
+214.98%
1年
+222.68%
查看详细走势图
TradingKey Nektar Therapeutics股票评分
单位: USD 更新时间: 2025-12-23操作建议
Nektar Therapeutics当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名117/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价107.29。中期看，股价处于下降通道。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nektar Therapeutics评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
8
位分析师
买入
评级
107.286
目标均价
+87.30%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Nektar Therapeutics亮点
亮点风险
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
业绩增长期
公司处于发展阶段，最新年度总收入98.43M美元
估值低估
公司最新PE估值-5.89，处于3年历史低位
机构减仓
最新机构持股9.79M股，环比减少18.98%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值278.54K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.66
Nektar Therapeutics新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nektar Therapeutics简介
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
公司代码NKTR
公司Nektar Therapeutics
CEORobin (Howard W)
网址https://www.nektar.com/
常见问题
Nektar Therapeutics(NKTR)的当前股价是多少？
Nektar Therapeutics(NKTR)的当前股价是 43.940。
Nektar Therapeutics的股票代码是什么？
Nektar Therapeutics的股票代码是NKTR。
Nektar Therapeutics股票的52周最高点是多少？
Nektar Therapeutics股票的52周最高点是66.920。
Nektar Therapeutics股票的52周最低点是多少？
Nektar Therapeutics股票的52周最低点是6.480。
Nektar Therapeutics的市值是多少？
Nektar Therapeutics的市值是863.53M。
Nektar Therapeutics的净利润是多少？
Nektar Therapeutics的净利润为-118.96M。
现在Nektar Therapeutics(NKTR)的股票是买入、持有还是卖出？
根据分析师评级，Nektar Therapeutics(NKTR)的总体评级为买入，目标价格为107.286。
Nektar Therapeutics(NKTR)股票的每股收益（EPS TTM）是多少
Nektar Therapeutics(NKTR)股票的每股收益（EPS TTM）是-7.553。
相关品种
